Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event? by Arsenault, Julie et al.
RESEARCH ARTICLE Open Access
Do patients with recurrent episodes of
campylobacteriosis differ from those with a single
disease event?
Julie Arsenault
1,3*, André Ravel
2,3, Pascal Michel
2,3, Olaf Berke
4, Pierre Gosselin
3,5
Abstract
Background: Although Campylobacter is the leading cause of reported bacterial gastro-enteritis in industrialized
countries, little is known on its recurrence. The objective of this study is to describe the risk and the patient
characteristics of recurrent episodes of human campylobacteriosis reported in Quebec.
Methods: Laboratory-confirmed cases of campylobacteriosis reported in the province of Quebec, Canada, through
ongoing surveillance between 1996 and 2006 were analyzed. The risk of having a recurrent episode of
campylobacteriosis was described using life table estimates. Logistic regression was used to assess if gender, age
and patient residential location were associated with an increased risk of recurrence.
Results: Compared to the baseline risk, the risk for a recurrent disease event was higher for a period of four years
and followed a decreasing trend. This increased risk of a recurrent event was similar across gender, but higher for
people from rural areas and lower for children under four years of age.
Conclusions: These results may suggest the absence of durable immunity or clinical resilience following a first
episode of campylobacteriosis and periodical re-exposure, at least among cases reported through the surveillance
system.
Background
In Canada, infection by Campylobacter spp. is the lead-
ing cause of bacterial gastro-enteritis, with an average of
39 cases per 100,000 people reported annually over the
last decade [1]. However, given the mild clinical expres-
sion of most Campylobacter infections, this reflects an
underestimation of the true burden in the population, as
only a fraction of people affected consult their physician
and have stool samples submitted for culture [2].
In Canada as in many other countries, human campy-
lobacteriosis is a reportable disease. Regional public
health authorities are notified of confirmed cases and
selected information is then gathered into surveillance
databases. These databases can then be used in epide-
miological investigations as sources of information for
evaluating individual or environmental risk factors [3,4].
It was recently proposed that acquired immunity to the
infection could bias results from risk factor analysis by
reducing the risk of developing the disease in areas of
high exposure [5].
Following an infection with Campylobacter, most peo-
ple develop a humoral immune response. Circulating
antibodies are detectable six to seven days after the
onset of the disease [6]. The antibody peak occurs
within 7 days to 4 weeks, depending on the specific
serum immunoglobulin, and then declines over several
months [6]. Although the development of antibodies fol-
lowing a Campylobacter infection is well recognized,
their protective role is poorly understood, especially in
populations living in developed countries [6].
One of the potential avenues of exploring the possible
protective effect of immunity is through studying recur-
rence. Immunity following a first episode of campylo-
bacteriosis would be associated with a reduced risk for
subsequent events, which might also vary in time and
according to patient characteristics. Characterization of
the risk of recurrent episodes may also bring valuable
insight to the question of whether or not to include
* Correspondence: julie.arsenault@umontreal.ca
1Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-
Hyacinthe, Quebec, J2S 7C6, Canada
Full list of author information is available at the end of the article
Arsenault et al. BMC Public Health 2011, 11:32
http://www.biomedcentral.com/1471-2458/11/32
© 2011 Arsenault et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.patients with multiple reports of the disease in risk fac-
tor analyses. The objective of this study is therefore to
describe the risk of having a recurrent episode of cam-
pylobacteriosis in relation to patient characteristics.
Methods
This study was designed as a retrospective analysis of
human campylobacteriosis cases reported through
ongoing surveillance in the province of Quebec, Canada,
between January 1, 1996 and December 31, 2006. Cases
from non-organized territories, incompletely enumerated
First Nations reserves, and areas located north of the
55th parallel were excluded.
Case data
Following approval of the project by the research ethics
board of the Montreal Health and Social Services
Agency, all laboratory-confirmed cases of campylobac-
teriosis were retrieved from each the health region’s
reportable disease database. Case information extracted
includes a de-identified record number, age, gender,
Campylobacter species isolated, various dates related to
onset and report, place of residence, and outcome.
Cases were geocoded at the municipality level (using
2006 boundaries). Patients were then classified as living
in an urban region if their municipality of residence was
entirely within an urban area, as rural if entirely outside,
or as semi-urban if otherwise. An urban area was
defined according to Statistics Canada as an area with a
population of at least 1,000 people and no fewer than
400 persons per km
2 (Statistics Canada, 2003).
Population data
Population census data by age, gender, and census sub-
divisions (CSD) were obtained from Statistics Canada
for the census years of 1996, 2001, and 2006. A
weighted average annual population for each CSD was
calculated over the three census years using 0.25, 0.5,
and 0.25 weights, respectively. A weighted average
annual population by urbanicity was also calculated
using a similar method.
Date of onset
For each reported case, the date of onset was retrieved
directly from the database when available. If this date
was missing, an estimation was performed using a
“proxy date” based on the first of the following dates
with a non-missing value: date of sample collection,
date of physician notification, date of laboratory notifi-
cation, date of reception of physician report by authori-
ties, and/or date of reception of laboratory report by
authorities. When date of onset had to be estimated,
the median time period (in days, by health region)
between the onset and proxy date was subtracted from
a case’s specific proxy date and used as the estimated
date of onset.
Recurrent episodes
Reported cases of recurrent episodes of campylobacter-
iosis were identified using unique de-identified record
numbers. Episodes of campylobacteriosis occurring
within 90 days of the date of onset of a prior episode
were excluded sincethese cases were diagnosed within
the recognized reported interval for duration of bacterial
excretion [7,8] and in consideration of the 90 day cut-off
time used by health officers for multiple entry detection
and removal during the validation process of reportable
disease databases [9].
Descriptive analyses
Descriptive statistics were used to investigate the fre-
quency distribution of patients according to the number
of episodes of campylobacteriosis reported, and the dis-
tribution of the time lag between two consecutive epi-
sodes. For patients with multiple episodes, the
association between Campylobacter species (jejuni, coli,
etc.) isolated in first and second episodes was tested
using the exact McNemar test and performed in SAS
9.2.
The baseline incidence of campylobacteriosis was esti-
mated by taking all first episode cases and dividing
them by the average population. This estimation was
performed for all combined cases and then stratified by
gender, age, and urbanicity. Age of patients was classi-
fied as 0-4 yrs, 5-14 yrs, 15-44 yrs, 45-64 yrs, and >65
yrs. A confidence interval (95%) for the average baseline
incidence of campylobacteriosis was estimated under the
normal distribution assumption, and results were then
converted to an annual rate per 100,000 people.
Survival analyses
The annual risk of having a recurrent episode of campy-
lobacteriosis was estimated among reported cases using
a survival analysis. These cases were then stratified by
gender, age, and urbanicity and a survival analysis was
performed again on each category. Survival function was
inferred from life-table estimates in SAS 9.1. Time of
entry of each patient into the analysis was set as the
date of onset of the first episode plus 90 days. However,
for the analysis by age group, time of entry was set as
the day at which the patient reached the lower bound of
the age group studied plus 90 days. For the analysis by
urbanicity, the category was determined by the type of
region noted upon first episode, since information on
changes in residency regions was not complete. Time-
to-event was estimated as the interval of time between
the time of entry and a second episode. Right censoring
was used for patients with no other reported episodes,
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entry in the analysis and the last day of the study. For
the analysis by age group, right censoring was also used
when the age of the patient reached the upper bound of
the age group studied. The risk of campylobacteriosis
with a 95% confidence interval was estimated at the
mid-point of 6-month intervals, and the risk was con-
verted to an annual rate per 100,000 people. However,
for the analyses by gender, age, or urbanicity, the stu-
died time period was restricted to the 5 years following
the first episode, with the risk calculated at the mid-
point of this 5-year interval. Due to the low number of
cases in these stratum-specific analyses, the use
of 6-month intervals would have led to very large
confidence intervals.
Logistic regression
Logistic regression was used to evaluate patient charac-
teristics in relation to the occurrence of reported
episodes of campylobacteriosis. Three models were
developed, one for each patient characteristic studied
(i.e., gender, age group, and urbanicity). Given that we
did not collect direct information from non-cases, a
simulated individual database was created for each
model, taking into consideration information from the
population-at-risk over a 5 year period. The outcome
was the report of an episode of campylobacteriosis (yes,
no) and the following explanatory variables were
included: previous episode of campylobacteriosis (yes,
no), characteristics of patient (as categories), and their
interaction. The database was created in two steps. First,
the number of records for people without a previous
reported episode of campylobacteriosis was estimated
separately for gender, age group, or urbanicity as the
average population at risk in the study area based on
census information. Among these, a number of records
corresponding to the average number of reported cases
(first episode) for a 5 year period were set as having had
a positive outcome. For example, in the model including
gender, 3,519,216 males were included in the analysis as
having had no previous reported episode of campylobac-
teriosis; among them, 7155 were set as having had a
positive outcome (i.e. 15,742 reported male cases for the
study period/11 years of the study period*5 years) and
the remaining 3,512,061 males were set as having had a
negative outcome (see Table 1). In the second step,
records for people with a previous episode were added
to the database and set as the effective population at
risk for each category of patient characteristics esti-
mated from the survival analysis for the 5 years follow-
ing a reported episode of campylobacteriosis (see
Table 1). Outcome was then set as positive for the num-
ber of patients corresponding to the number of second
episodes of campylobacteriosis reported (for example,
12,485 males were included as having had a first epi-
sode, among which 163 had a positive outcome). Most
patients with two episodes of campylobacteriosis were
included twice in the analysis. A hierarchical backward
procedure was used for model selection using P ≥ 0.05
based on the likelihood ratio test (LRT) as criterion for
removal (performed in SAS 9.2). The odds ratio (OR)
was used to present results.
Results
A total of 29,407 episodes of laboratory-confirmed cases
of campylobacteriosis were recorded in the surveillance
database between 1996 and 2006, inclusively. From
these, 158 were excluded because a previous episode
was recorded within 90 days of the date of onset. The
remaining 29,249 episodes were linked to 28,905
patients for an average of 1.01 episodes per patient.
Mortality related to campylobacteriosis was recorded for
6 patients.
In assessing the completeness of information for the
estimation of the date of onset, the percentages of
records with valid information were: 72% for a date of
sample collection, 15% for date of physician notification,
16% for date of reception of physician report, 96% for
date of laboratory notification, 99% for date of reception
of laboratory report, and 38% had a valid date of onset.
Consequently, the onset date was mostly estimated
based on the actual reported date of onset (38%) or on
t h ed a t eo fl a b o r a t o r yn o t i f i c a t i o n( 6 1 % ) .T h ev a r i o u s
intervals of time used for the estimation showed impor-
tant variations among health regions, as presented in
Additional file 1: Proxy dates for estimating date of
onset. For the 28,905 patients, 328 (1.1%) had 2 reported
episodes, 8 (0.03%) had three reported episodes, and
none had more than 3 episodes. The distribution of the
lag time between the first and second episode is pre-
sented in Figure 1. Among the 336 patients with recur-
rent episodes, 90% resided in the same municipality and
93% in the same region (rural, semi-urban, or urban) at
the time of their first two reported episodes. The per-
centage of patients who had moved from an urban
region to another region type between their two epi-
sodes was similar to the percentage that had moved
from a rural region to another one (9.9% versus 8.1%).
No statistically significant association was observed
between the Campylobacter species isolated in the first
and second episode (P = 1.00, McNemar exact test).
This analysis was restricted to patients with only Cam-
pylobacter jejuni or Campylobacter coli isolated in their
first or second episode (n = 210), considering the low
number of reported cases for other species (Table 2). It
is worth noting that among cases with Campylobacter
coli isolated in the first episode, 36.8% also had Campy-
lobacter coli isolated in the second episode, although
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the entire dataset (considering only episodes with a sin-
gle species isolated). Further exploration of the data
reveals that among these 210 isolates, the proportion of
Campylobacter coli isolates was similar according to the
level of urbanicity, estimated at 5.8% in semi-urban
areas, 11.5% in rural areas and 11.3% in urban areas
(P = 0.25, Chi-square test).
Description of the risk of recurrent episode
The overall incidence rate of recurrent campylobacterio-
sis decreased from 490 per 100,000 people per year
within the first 6 months following an episode, to 150
per 100,000 people per year by 4 years after the first epi-
sode (Figure 2). After 5 to 9 years, the incidence rate
was not statistically different from the incidence
observed in the population for a first episode. An
increased risk was also observed among all age, gender,
and urbanicity groups with a risk for a second episode
5.4 to 9.7 times higher than the risk estimated for a first
episode (Table 1).
According to the logistic regression model for gen-
der, no statistically significant interaction was observed
(P = 0.42, LRT) between gender and a previous episode
of campylobacteriosis within the ensuing 5 years, sug-
gesting that a previous episode increased the risk of
campylobacteriosis by the same magnitude for both
genders. This interaction was thus removed from the
model. The estimates for gender (OR = 1.3 for male ver-
sus female) and a previous episode (OR: 6.8) were statis-
tically significant (P < 0.001, LRT). For the logistic
regression model including age, the interaction between
a g ea n dap r e v i o u se p i s o d ew a ss tatistically significant
(P = 0.03, LRT). According to post-hoc pairwise com-
parisons, the increase in the risk of campylobacteriosis
following a first episode was lower in the 0-4 age group
compared to the other age groups (OR = 2.1 to 2.2, P >
0.02). Finally, according to the logistic regression model
including urbanicity, a statistically significant interac-
tion (P = 0.02, LRT) was observed between the type of
region and a previous episode. Post-hoc pairwise com-
parisons revealed that the impact of having had a pre-
vious episode of campylobacteriosis on the risk of a
subsequent episode was greater in rural areas compared
to semi-urban (OR = 1.4, P = 0.02) or urban (OR = 1.7,
P = 0.008) areas.
Table 1 Incidence rates according to patient characteristics
First episode (11 years of follow-up) Second episode (5 years of follow-up) Ratio in
rates
c
Charac-
teristics
Average population at
risk per year
Cases
a Episode per year per
100,000 (95% C.L)
Effective
population at risk
b
Cases
a Episode per year per
100,000 (95% C.L)
Gender
Male 3,519,216 15,742 40.7 (40.0, 41.3) 12,485 163 262.8 (222.5, 303.2) 6.5
Female 3,687,208 13,142 32.4 (31.9, 33.0) 10,540 121 230.9 (189.8, 272.1) 7.1
Age category (yrs)
d
≤4 389,854 2,406 56.1 (53.9, 58.4) 1,272 16 252.9 (129.0, 376.8) 4.5
5-14 890,700 2,774 28.3 (27.3, 29.4) 2,406 22 183.6 (106.9, 260.3) 6.5
15-44 3,097,425 15,351 45.1 (44.3, 45.8) 8,252 176 430.7 (367.1, 494.3) 9.5
45-64 1,872,161 5,262 25.6 (24.9, 26.3) 3,244 40 247.8 (171.0, 324.6) 9.7
≥65 955,915 3,032 28.8 (27.8, 29.9) 1,944 26 269.0 (165.6, 372.4) 9.3
Urbanicity
e
Rural 893,415 4,209 42.8 (41.5, 44.1) 3,247 62 385.6 (289.6, 481.6) 9.0
Semi-
urban
3,438,014 15,876 42.0 (41.3, 42.6) 12,780 170 267.8 (227.6, 308.1) 6.4
Urban 2,875,304 8,632 27.3 (26.7, 27.9) 6,889 51 148.6 (107.8, 189.4) 5.4
Total 7,206,733 28,905 36.5 (36.0, 36.9) 23,041 284 248.0 (219.2, 276.9) 6.8
Incidence rate of reported cases of campylobacteriosis with 95% confidence limits for first and consecutive episodes according to patient characteristics, Quebec,
1996-2006.
a Total number of cases observed during the follow-up period.
b The effective population at risk (ni’) is the total number of individuals followed in the 5-year period (ni) minus half the number of individuals censored (wi)
(ni’ =n i-wi/2).
c Estimated incidence rate for second episode vs. first episode.
d For the first episode, the age category is the age at the time of the episode (case) and census data for the age group (population). For the second episode,
patients were included in the analysis only for the period during which they were in the age category and if they had had an episode in the previous 5 years.
e Region of residence at time of first episode.
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According to our results, the risk of a recurrent episode
of campylobacteriosis was 248 for every 100,000 patients
per year on average for the first 5 years following a first
episode. This means that approximately 1.2% of patients
with a reported episode of campylobacteriosis suffer
from another episode within the next five years.
Although this percentage might seem low, it represents
a much higher risk than the one observed in the general
population.
The relatively high rate of recurrence in campylobac-
teriosis cases may suggest that people in Quebec, like in
other regions of industrialized countries, might be
exposed to Campylobacter at lower levels than needed
to develop an effective immunity. This would be in
agreement with other studies which conclude that the
development of immunity against Campylobacter is
most likely limited to developing countries, where indi-
viduals are most likely exposed to a highly contaminated
environment, characterized for example by a poor qual-
i t yw a t e rs u p p l yo rb yt h ep r e s e n c eo fp o u l t r yi nt h e
Figure 1 Interval of time between reported episodes. Interval of time between a first and a second episode of campylobacteriosis in
laboratory-confirmed reported cases in Quebec, 1996-2006 (episodes occurring in the first 90 days following the first episode were not
considered). Top: all cases. Bottom: cases reported between 1996 and 2001 and excluding episodes recurring after 5 years or more.
Table 2 Campylobacter species isolated
First episode Second episode (within a 5-year interval)
Species Number %
jejuni jejuni 172 92.5
coli 11 5.9
jejuni and coli 1 0.5
hyointestinalis 1 0.5
fetus 1 0.5
Total 186 100.0
coli jejuni 12 63.2
coli 7 36.8
jejuni and coli 0 0.0
Total 19 100.0
jejuni and coli jejuni 3 60.0
coli 2 40.0
jejuni and coli 0 0.0
Total 5 100.0
Campylobacter species isolated during the first two consecutive episodes of
campylobacteriosis among laboratory-confirmed cases reported in Quebec,
1996-2006 (n = 210 patients with recurrent episodes).
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tries is supported by children excreting the bacteria for
shorter duration and by disproportionately higher risk in
travellers [12]. In industrialized countries, the exposure
to Campylobacter is considered much lower, which
translates into lower incidence rates of campylobacterio-
sis in children and a lower percentage of carriers
[11,13,14]. One of the few documented instances of
acquired immunity to Campylobacter infection in indus-
trialized countries is with people professionally exposed,
such as poultry abattoir workers [15,16]. This fraction of
the population, although likely present among the cases
reported in the province of Quebec, is probably too
small to have had an impact in our study. Another
study conducted in Scotland found some evidence of
age-acquired immunity to common serotypes [17],
whereas immunity to common genotypes was proposed
as an explanation for reduction in incidence of campylo-
bacteriosis in some countries [18].
Our data did not show evidence of the development of
Campylobacter species-specific immunity, since people
with recurrent episodes were as likely to have been
infected twice by the same Campylobacter species. How-
ever, Campylobacter strains for the same species are
reported to present a high genetic diversity [19]. Thus,
immunity is expected to develop for strains sharing
similar antigenic properties, which could not be evalu-
ated in this study. This analysis could have been biased
by the exclusion of some cases involving other or
multiple species; however, this exclusion amounted to
only 1% of cases. It should be remembered that reported
cases represent only a small fraction of all cases occur-
ring in the population. It would be interesting to evalu-
ate if patients with more severe clinical presentations
are similar in terms of immune response and risk of
recurrence when compared to milder cases.
In addition to the lack of evidence of an acquired
immunity, a prior episode seems to increase the risk of
reporting a second episode of campylobacteriosis. Cam-
pylobacteriosis might cause long-term perturbations of
intestinal physiology leading to an increased susceptibil-
ity to enteric diseases in general [20]. Long-term patho-
physiological consequences of Campylobacter infections
are also supported by a Danish study that noted an
increased mortality following a reported episode of cam-
pylobacteriosis for the year following the episode, even
after adjustment for comorbidity [21]. Unfortunately, no
information was available on the significance of relapses
or recurrent episodes in the explanation of this excess
risk.
It is also possible that the higher risk is driven by
some sub-groups of the population with diseases that
predispose them to a high risk of recurrence. In the lit-
erature, there are reported cases of patients with hypo-
gammaglobulinemia who experienced recurrent episodes
of campylobacteriosis [22]; however, recurrent episodes
were closer in time than what we observed and a predis-
posing disease such as this is rare. Other diseases were
reported as risk factors for campylobacteriosis, including
AIDS, chronic intestinal diseases, diabetes, liver disease
and metastatic cancers [21,23-25]. The use of antacid or
antibiotics is also associated with a higher risk of cam-
pylobacteriosis [26-28]. This can also be the case for
people using corticosteroids. These drugs are commonly
prescribed for a wide variety of diseases such as asthma,
rheumatism, allergies, and renal disorders, and their
chronic use is associated with an increased risk of infec-
tious diseases [29].
Another sub-group at possible higher risk would be
travelers; according to surveillance data collected in the
region of Waterloo, 19% of reported cases of campylo-
bacteriosis were associated with international traveling
[30]. Travel-associated cases are likely overestimated in
surveillance databases, because people traveling abroad
in the days preceding a diarrheal episode are more likely
to seek medical advice, even after adjustment for disease
severity [31]. It is possible that people do develop
immunity against Campylobacter, but that such immu-
nity is not effective when exposed to uncommon strains
or to a highly contaminated environment when traveling
in developing countries. In the Quebec surveillance
database on reportable diseases, data on the occupation
of the patient and whether cases are related to out of
Figure 2 Risk of campylobacteriosis after a first episode.R i s k s
of campylobacteriosis (with 95% confidence limits) after a first
episode among laboratory-confirmed reported cases in Quebec,
1996-2006. Risks were calculated at the mid-interval of 6-month
periods following the first episode onset +90 days (dotted line:
average incidence rate of first episode in the population).
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patients respectively, making any analysis unfeasible.
From another perspective, people with a previous diag-
nosis of campylobacteriosis might be more inclined to
consult their physician when they experience another
episode of acute gastroenteritis. In fact, the overall risk
of campylobacteriosis in Canada has been estimated to
be approximately 1.5% per year [2], which is very close
to our 1.2% estimate.
T h eh i g h e rr a t eo fr e c u r r e n c ef o rt h o s ew i t hap r e -
vious infection of Campylobacter is suggestive of long-
term or recurrent rather than punctual exposure, for
example via an occupational exposure to animals, a
source of drinking water or food habits [32-34]. This
could be of particular importance for people living in
rural areas where infection through drinking raw milk
or being in direct contact with excreting farm animals is
more likely [32,35]. This could be also true for young
children who have closer contact with their environment
due to specific behaviors. A long-term or recurrent
exposure from a specific source is also suggested when
Campylobacter coli is frequently isolated (i.e. 36%) in
successive episodes but not commonly isolated in the
general population. Campylobacter coli is known to be
strongly associated with swine and certain environmen-
tal sources [36]. These speculations are supported by
our results which show that the risk of campylobacterio-
sis following a first reported episode is higher in infants
and people from rural regions.
Some assumptions underpinning this study must be
mentioned. First, a proxy estimation was used for the
date of campylobacteriosis onset, which is a potential
source of error. However, we do not have reason to
believe that this method biases the results. Moreover,
the possibility that chronic cases were identified as
recurrent cases is low. In fact, cases occurring less than
3 months from first episodes were excluded, and campy-
lobacteriosis typically lasts less than 7 days [37,38] and
bacterial excretion following the resolution of clinical
signs persists for only two to nine weeks [7,39]. It was
a s s u m e dt h a ta l lp e o p l eh a v i n gh a dar e p o r t e de p i s o d e
of campylobacteriosis remained at risk of having another
one up to the end of the study. However, information
on patient mortality occurring after the episode was not
available, and episodes reported in two different health
regions for a single patient were not necessarily identi-
fied by a single identifier. Despite this fact, any death or
move would have led to a reduction in the number of
reported episodes, and ultimately to the same conclu-
sions. Based on our observations and other reports, the
fatality rate associated with reported campylobacteriosis
episodes in Canada is typically less than 1% [40]. Like-
wise, the impossibility of linking cases occurring in a
single patient but reported in different health regions
would also lead to an underestimation of the risk of
recurrent episodes, because this would lead to underesti-
mating the number of cases of recurrent episodes.
Finally, a misclassification bias could be present in our
study, since patients with only one reported episode
could have had another episode prior to our study time
period. Likewise, not all patients stayed in the same
region type for the entire study period; city dwellers can
also move to cottages on a regular basis for short or
long periods of time, yet remain classified as urban for
statistical purposes. These misclassifications, if present,
w o u l dh a v el i k e l yp r o d u c e dm o r ec o n s e r v a t i v er e s u l t s
with a reduction of the risk difference observed.
We used a logistic model to study the risk of recur-
rent episodes according to patient characteristics. This
model did not take into account the correlation between
individuals included twice in the analysis. Attempts were
made to fit models using multi-level or generalized esti-
mating equation methods but no convergence was
obtained. The restriction of the analysis to patients hav-
ing had a first episode would have led to misleading
results due to the inability to adjust forr stratum-specific
baseline risks. Development and validation of statistical
models for studying recurrent episodes in this setting
could be an issue to consider [41].
Data arising from surveillance systems, although
imperfect, represent an invaluable source of information
for studying the epidemiology of infectious diseases such
as campylobacteriosis. However, given the experience of
this study, such data would be further enhanced by cap-
turing information related to domestic travel, underlying
medical conditions, antacid or antibiotic use, and occu-
pational information.
Conclusions
When compared to a baseline risk, the risk for a recur-
rent episode of campylobacteriosis was increased for
four years and followed a decreasing trend. This
increased risk of a recurrent event was similar across
gender, but higher for people from rural areas and
l o w e rf o rc h i l d r e nu n d e rf o u ry e a r so l d .T h e s er e s u l t s
may suggest the absence of durable immunity or clinical
resilience following a first episode of campylobacteriosis
and periodic re-exposure, at least among cases reported
through the surveillance system. A follow-up study on
recurrent cases might be useful for understanding speci-
fic patient characteristics involved in this higher risk of
recurrence. These results also suggest that recurrent
cases of campylobacteriosis should be excluded from
risk factor analyses, or that the correlation between epi-
sodes occurring in the same individual should be taken
into account. Lastly, this data revealed some level of
specificity in the epidemiology of campylobacteriosis for
population sub-groups such as children and people
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teriosis would benefit from being informed about poten-
tial sources of contamination and adequate preventive
measures.
Additional material
Additional file 1: Proxy dates for estimating date of onset.Availability
of proxy dates for estimating the date of onset and median interval
between date of onset and proxy dates among reported cases of
campylobacteriosis, by health regions, Quebec, 1996-2006 (Table).
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